Artivion (NYSE:AORT) CEO James Mackin Sells 13,936 Shares

Artivion, Inc. (NYSE:AORT) CEO James Mackin sold 13,936 shares of the company’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $35.69, for a total transaction of $497,375.84. Following the completion of the sale, the chief executive officer directly owned 766,095 shares in the company, valued at approximately $27,341,930.55. The trade was a 1.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Artivion Stock Performance

Shares of AORT traded up $0.96 during mid-day trading on Thursday, reaching $36.74. The company had a trading volume of 19,709 shares, compared to its average volume of 389,388. The stock has a market capitalization of $1.76 billion, a P/E ratio of 183.69 and a beta of 1.59. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.25. The stock has a 50 day moving average of $42.27 and a two-hundred day moving average of $43.08. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The firm’s revenue was up 19.2% compared to the same quarter last year. On average, analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Key Stories Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Short interest fell sharply in February, declining 15.4% to 1,386,551 shares as of Feb. 13 (about 3.2% of shares sold short and a 2.8 days‑to‑cover). Lower short interest reduces immediate bearish pressure and can support the stock.
• Negative Sentiment: Significant insider selling across the leadership team: CEO James P. Mackin sold a total of 34,898 shares across Feb. 23–24 (about ~$1.29M at the reported prices); EVP Lance A. Berry, SVPs and other named officers also sold multiple blocks (each reducing holdings by ~1–5%). These are open‑market sales (disclosed on Form 4s) and may be interpreted as executives taking liquidity or rebalancing — but the breadth and size of the sales can pressure sentiment and share price. CEO Form 4 EVP Form 4 Other officer Form 4s

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Citizens Jmp lifted their price target on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $58.00 price objective on shares of Artivion in a report on Monday, February 2nd. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 target price on shares of Artivion in a research note on Friday, November 7th. Canaccord Genuity Group dropped their price target on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Finally, Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $48.97.

Hedge Funds Weigh In On Artivion

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its holdings in Artivion by 211.9% in the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after buying an additional 748,119 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Artivion in the fourth quarter valued at about $746,000. Susquehanna Portfolio Strategies LLC increased its position in Artivion by 21.5% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company’s stock worth $1,849,000 after purchasing an additional 7,186 shares during the last quarter. Occudo Quantitative Strategies LP purchased a new position in Artivion during the fourth quarter worth about $248,000. Finally, Millennium Management LLC raised its stake in Artivion by 1.0% during the fourth quarter. Millennium Management LLC now owns 91,816 shares of the company’s stock worth $4,188,000 after purchasing an additional 893 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.